EGFR and lung adenocarcinoma: With the continued advancement of molecular biology, the treatment paradigm for lung adenocarcinoma has shifted from conventional approaches based on histopathological and clinical characteristics toward precision medicine guided by individual genetic alterations—most notably, mutations in the epidermal growth factor receptor (EGFR) gene.